Jubilant Draximage bags USFDA nod for Technetium Mertiatide Injection
Noida: Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Draximage Inc has announced that it has received approval from the US Food and Drug Administration (USFDA) with regards to the Company's new drug application (NDA) submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kit for the Preparation of Technetium (Tc 99m) Mertiatide Injection.
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients aged 30 days and older.
Read also: Jubilant Pharma arm to raise Rs 3,186 crore loan from Standard Chartered Bank to repay debt
The product enables providing renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex. This approval is effective from Jan 30, 2023.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.